BIOiSIM® is a first-in-class 'virtual drug development engine' that offers unprecedented value for the drug development industry by narrowing down the number of drug compounds that offer anticipated value for the treatment or cure of specific illness or disease.
“At a time when numerous smaller organizations are over-selling their AI efforts as cure-alls, I found VSL's down-to-earth but competent and insightful approach very refreshing...I would not hesitate to recommend them for organizations looking for professional and knowledgeable external ML solutions.”
How can we help you?
Services
We provide technology enabled services to address your translational challenges guided by our unique Translational Index® capability. Engage with our professionals to quickly impact your program's journey toward more successful clinical trial outcomes.
Partnership
We partner with organizations to co-develop new drugs using our platform to predict translation and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.
Our models are built on data from thousands of compounds across 7 species, leading to a robustness rarely seen in the industry.
The BIOiSIM® platform can be used before preclinical animal trial start, allowing earlier insights and savings in expensive outsourced experimentation.
VeriSIM Life has shown that the best models are developed by using a hybrid mixed-model approach to drug insights, leading to greater accuracy and scalability.
With a focus on human outcomes, the platform has at its core a translability engine that transforms insights across species.
The team employees a continuous improvement process to iterate on data stability, improve models, and provide an always up-to-date software service.
The flexibility of the platform and generations of customer-ready tools allows for development of custom models and validations within weeks.
BIOiSIM® enables your team with a novel platform that focuses your development efforts on the drug compounds that are more likely to deliver on the anticipated value for the treatment or cure of a specific disease.
With our framework, we can quickly develop custom, specific models.
Validated with both FDA and proprietary compounds.
We are always adding new functionality and expanding the domain of applicability.
We simulate various routes of administrations such as IV, oral, and transdermal and others.
Our platform is cloud-based and generates predictions in seconds.
Our model extracts conclusions from complex and convoluted data.
Speak to one of our experts today
VeriSIM Life’s first-in-class, drug decision engine, BIOiSIM, offers actionable insights of unprecedented value to the drug development industry.
Avoid the design and pursuit of dead end candidates. Guide decision-making with BIOiSIM’s Translational Index®, which advances only the most promising drug candidates through R&D to investigational new drug (IND) application.
BIOiSIM's integrated drug design and development platform identifies new drug candidates with clinical success designed in from day one, while flexibly adapting to address a range of translation challenges – reducing the time it takes to get to IND status by an average of 2.5 years.
With greater accuracy and scalability, BIOiSIM’s robust, hybrid AI/ML engine reduces the need for unnecessary in vivo experimentation, representing a $3 million cost savings when compared to conventional testing.
Novel drug discovery search space
Real validation simulations and counting
Simulation scenario capacity
Than other non-AI enhanced models
Get to IND status 2.5 years faster
The BIOiSIM platform combines a vast chemical search space, thousands of validation data sets, multi-compartmental models, machine learning, deep learning and large language models to achieve next-level chemical and biological relevance for drug design and translation agnostic to indication or modality.
Provides predictions without the need for large empirical datasets that are translatable across different species, routes of administration and therapeutic areas, greatly reducing overfit and specialization.
Undergoes frequent algorithm checks to reinforce learning, while tracking changes to predictiveness baselines; ongoing training and validation simulations allow for continuous learning and accuracy.
Drives high-value decisions through the platform’s cloud-based computational system – fully scalable, optimized for high-speed processing, and supporting 800 billion total potential simulation scenarios.
Preserves scientific context and maintains structural integrity, boasting a growing, proprietary, structure-related data lake for >3M+ compounds, >5000+ unique animal and human validation datasets, physiological parameters of 196+ different subject populations. Uniquely augmented with relevant synthetic data.
We partner with biotech and pharma clients to identify successful novel candidates for difficult targets. Collaborate with a discovery enabler with the unique ability to merge biological relevance with target engagement chemistry, designing in clinical success from day one.
We partner with organizations to co-develop new drugs using the BIOiSIM platform to more accurately predict translatability and reduce R&D waste. These deep collaborations significantly de-risk the selection of new candidates and shorten development time.
Our mission at Debiopharm is to develop tomorrow’s standard of care for cancer and improve patient quality of life. Accelerating the translation of our research to clinical success is a priority, and our work with VeriSIM Life is focused on this critical objective. With insights from the BIOiSIM platform, we believe our innovative therapies will rapidly move closer to addressing the unmet needs of cancer patients worldwide.